Payment overview · 2025
General Payments
$1,735.86
95 reported records · 21 companies
Healthcare provider profile · identity verified
Daniel John Callahan, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · PEACHTREE CITY, GA · NPI 1265998439
Verified facts
What the public records show
CMS Open Payments records show Daniel John Callahan, PA-C received $1,735.86 in general payments during 2025 across 95 reported records.
AstraZeneca Pharmaceuticals LP accounted for 15.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Mounjaro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $276.55 | 15.9% | 12 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $219.93 | 12.7% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $194.87 | 11.2% | 17 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $167.61 | 9.7% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $149.96 | 8.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.86 | 7.2% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $81.72 | 4.7% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $81.31 | 4.7% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $79.51 | 4.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.20 | 3.7% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.76 | 2.8% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.88 | 2.5% | 2 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $39.30 | 2.3% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.40 | 1.9% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.61 | 1.3% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $21.73 | 1.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $21.01 | 1.2% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.05 | 1.2% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $19.12 | 1.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.76 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $13.72 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,735.86 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $186.84 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $167.61 | 11 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $146.65 | 10 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $127.27 | 6 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $119.38 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $100.55 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $100.22 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $94.65 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.71 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $86.52 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $86.52 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $81.72 | 5 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $81.31 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.08 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.99 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.20 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.20 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $63.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.87 | 3 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $43.88 | 2 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $39.30 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.40 | 2 | 2025 |
Source payment records
|
|||||
| Axonics Normalized: axonics |
Device | Boston Scientific Corporation | $22.61 | 1 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $21.01 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.05 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
57 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 122 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 106 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 39 |
| Prednisone | Prednisone | 60 | 39 |
| Mounjaro | Tirzepatide | 57 | 12 |
| Farxiga | Dapagliflozin Propanediol | 52 | 13 |
| Omeprazole | Omeprazole | 47 | 19 |
| Levothyroxine Sodium | Levothyroxine Sodium | 46 | 15 |
| Telmisartan | Telmisartan | 46 | 15 |
| Lisinopril | Lisinopril | 41 | 15 |
| Sertraline Hcl | Sertraline Hcl | 36 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 15 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 32 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Losartan Potassium | Losartan Potassium | 30 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 23 |
| Metformin Hcl Er | Metformin Hcl | 29 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 28 | 21 |
| Azithromycin | Azithromycin | 27 | 24 |
| Ondansetron Odt | Ondansetron | 27 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 22 |
| Fluconazole | Fluconazole | 26 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 12 |
| Carvedilol | Carvedilol | 24 | suppressed |
| Furosemide | Furosemide | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Gabapentin | Gabapentin | 20 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Metformin Hcl | Metformin Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Famotidine | Famotidine | 15 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 11 |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,735.86 · 95 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, Axonics, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, Jornay PM, Korlym, MAKO, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SUBLOCADE, Symbravo, TZIELD, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, XYOSTED, Xelstrym, ZAVZPRET, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error